Abstract: Methods for treating a bacterial infection by using a metallo-desferrioxamine complex.
Type:
Grant
Filed:
August 13, 2007
Date of Patent:
March 25, 2014
Assignees:
University of Washington, Hadasit Medical Research Services and Development Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
Inventors:
E. Peter Greenberg, Ehud Banin, Eyal Banin, Eduard Berenshtein, Mordechai Chevion
Abstract: A method of diagnosing pancreatic cancer in a subject is provided. The method comprising determining a level and/or activity of at least one saliva secreted marker in a saliva sample of the subject wherein an alteration in said marker with respect to an unaffected saliva sample is indicative of the pancreatic cancer.
Type:
Application
Filed:
December 13, 2011
Publication date:
March 20, 2014
Applicant:
Hadasit Medical Research Services and Development Ltd.
Abstract: The present invention provides a device for iontophoretic delivery of a drug to on into a tissue, comprising an arrangement that prevents operation of the device at a current density that is higher than a predetermined value, the arrangement including first means responsive to a first data item, indicative of the surface area through which the current is to pass, as to set the maximal current allowed at the surface area indicated by the data item. The present invention also provides a method for iontophorectivally administering drug to or into a tissue, comprising determination of a maximal allowed level of current density and preventing application of current density above the maximal allowed level.
Type:
Grant
Filed:
March 3, 2005
Date of Patent:
March 4, 2014
Assignees:
Hadasit Medical Research Services & Development Limited, Yissum Research Development Company of the Hebrew University of Jerusalem
Inventors:
Abraham J. Domb, Joseph Frucht-Pery, Mervyn Shapiro
Abstract: A physical phantom reference to control for variability of computed tomography measurement results duplicates the density curve of blood perfusion of contrast material in a healthy aorta or large artery to normalize observed changes in healthy arterial blood perfusion when calculating the reduction in tumor blood perfusion between two examination times. In one embodiment, a plurality of compartments with different concentrations of contrast material corresponding to a density curve of blood perfusion of a healthy tissue are positioned-in a screening field of a CT machine so the CT machine images the compartments when it images the healthy tissue. In another embodiment, a pipe containing fluid receives an injection of contrast material from the injector when the injector injects the contrast material into the patient, the pipe having sections of varying diameter so the sections together correspond to a blood perfusion curve of the contrast material in a healthy tissue.
Type:
Grant
Filed:
February 3, 2010
Date of Patent:
January 28, 2014
Assignee:
Hadasit Medical Research Services and Development Ltd.
Abstract: An article of manufacture comprising packaging material and a pharmaceutical composition is disclosed, the article of manufacture being identified in print in or on the packaging material for treatment of an immunity-related disease in a subject in need thereof. The pharmaceutical composition comprises a pharmaceutically acceptable carrier and, as an active ingredient, a compound being capable of modulating an interaction between a heparin-binding domain of a thrombospondin and a receptor of the heparin-binding domain.
Type:
Grant
Filed:
June 20, 2006
Date of Patent:
December 31, 2013
Assignees:
Hadasit Medical Research Services and Development Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem
Inventors:
Dror Mevorach, Alon Krispin, Yaniv Bledi, Michal Linial
Abstract: The present invention concerns isolated PAR1 cytoplasmic tail (c-tail) peptides and isolated PAR2 cytoplasmic tail (c-tail) peptides, as well as compositions comprising these peptides, uses thereof and methods of treating various diseases, in particular cancer.
Type:
Application
Filed:
December 29, 2011
Publication date:
December 12, 2013
Applicant:
Hadasit Medical Research Services and Development Limited
Abstract: The present application discloses methods expanding SCs in an undifferentiated state, the methods comprising incubating undifferentiated SCs in suspension within a culture system comprising basic medium and knockout serum replacement (KOSR). The methods may also be applicable for selective spontaneous or directed differentiation of SCs into a selected population of somatic cells from a culture system of SCs in suspension, the method further comprising incubating said undifferentiated SCs in culture system that support respectively, spontaneous or directed differentiation of SCs into the selected population of somatic cells. The present application also discloses a culture system for expansion of stem cells (SCs) comprising a suspension of undifferentiated stem cells within basic medium and knockout serum replacement (KOSR). The methods and culture system of the invention may be used for large scale production of differentiated cells.
Type:
Grant
Filed:
April 2, 2007
Date of Patent:
December 3, 2013
Assignee:
Hadasit Medical Research Services & Development Limited
Abstract: A method of diagnosis is disclosed. The method comprises using a display device for presenting a motion perception test to a subject and determining a subject response to the motion perception test. The response can be used for assessing presence or absence of demyelination and/or remyelination.
Type:
Application
Filed:
October 18, 2012
Publication date:
November 28, 2013
Applicant:
Hadasit Medical Research Services and Development Ltd.
Abstract: The present invention provides peptides and peptide analogs capable of inhibiting the activity of protein kinase C. The invention discloses use of such peptides and analogs for preparation of pharmaceutical compositions and methods for prevention, delay, suppression or treatment of type 2 diabetes using such compositions.
Type:
Grant
Filed:
June 28, 2006
Date of Patent:
November 5, 2013
Assignee:
Hadasit Medical Research Services & Development Ltd.
Abstract: Provided is a method including providing a population of cells including a target type of differentiated cells having a pre-identified cytoskeletal profile and at least one cell selected from undifferentiated cells, differentiating cells and differentiated cells being different from the target type of differentiated cells; and incubating the population of cells with a cytotoxic agent, in an amount and for a time period effective to form a modified population of cells including predominantly or consisting essentially of the target type of differentiated cells. The pre-identified cytoskeletal profile can include the presence of class III ?-tubulin on neuronal cells and the population of cells includes neural cells and neuronal cells.
Type:
Application
Filed:
September 27, 2011
Publication date:
October 24, 2013
Applicant:
Hadasit Medical Research Services & Development Limited
Inventors:
Sharona Cohen Evenram, Benjamin Reubinoff
Abstract: A highly controlled and precise system, device and method for tissue and cellular alteration and treatment below or at surfaces with a laser. The present invention is characterized by ultra low levels of collateral damage as defined by physiologically relevant tests that measure tissue viability. The operation of the present invention is based on spectrally confining the interaction between laser energy and a targeted tissue including an essential element for physiologically relevant tests for monitoring tissue viability.
Type:
Application
Filed:
May 6, 2013
Publication date:
September 19, 2013
Applicant:
Hadasit Medical Research Services and Development Ltd.
Abstract: A particle including at least one aliphatic polymer having anti-microbially active quaternary ammonium groups chemically bound thereto, is provided. The particle may be used to inhibit populations of microorganisms and biofilms. Also provided are methods for the preparation of such particles and uses thereof for the inhibition of microorganisms.
Type:
Grant
Filed:
January 1, 2006
Date of Patent:
September 17, 2013
Assignees:
Hadasit Medical Research Services & Development Limited, Yissum Research Development Company of the Hebrew University of Jerusalem
Inventors:
Abraham J. Domb, Ervin Weiss, Nurit Beyth, Ira Farber, Michael Perez Davidi
Abstract: The invention provides methods and uses of different soybean extracts, for example, enzymatic, hexane, ethanol or aqueous soybean extracts and combinations thereof for the treatment of hepatic disorders, drug induced hepatic injury, the Metabolic Syndrome or an immune-related disorder in a subject in need thereof. The invention further provides pharmaceutical compositions, kits and methods thereof for treating and preventing hepatic disorders.
Type:
Application
Filed:
August 4, 2011
Publication date:
August 8, 2013
Applicant:
Hadasit Medical Research Services and Development Ltd.
Abstract: Novel epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitors, pharmaceutical compositions including same and their use in the treatment of EGFR-TK related diseases or disorders are disclosed. Novel radiolabeled EGFR-TK inhibitors as their use as biomarkers for medicinal radioimaging such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) and as radiopharmaceuticals for radiotherapy are further disclosed. The disclosed EGFR-TK inhibitors comprise a polyalkylene glycol moiety and/or a hydroxy-containing moiety and are characterized by improved solubility, biostability and bioavailability. Processes of preparing the disclosed EGFR-TK inhibitors and of radiolabeling same, via, for example, one-step radiosyntheses, are also disclosed.
Type:
Grant
Filed:
March 7, 2007
Date of Patent:
June 11, 2013
Assignees:
Hadasit Medical Research Services and Development Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
Inventors:
Eyal Mishani, Samar Dissoki, Galith Abourbeh, Alexander Levitzki
Abstract: The present invention provides compositions, methods and kits for diagnosing cancer, specifically the diagnosis of colorectal cancer (CRC). More specifically, the invention provides simple assays, with high sensitivity and specificity for CRC, wherein a panel of microRNA (miRNA) are used as biomarkers.
Type:
Application
Filed:
April 14, 2011
Publication date:
May 30, 2013
Applicant:
HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
Inventors:
Aviram Nissan, Stella Mitrani Rosenbaum, Nadia Ilyayev, David Halle
Abstract: A highly controlled and precise system, device and method for tissue and cellular alteration and treatment below or at surfaces with a laser. The present invention is characterized by ultra low levels of collateral damage as defined by physiologically relevant tests that measure tissue viability. The operation of the present invention is based on spectrally confining the interaction between laser energy and a targeted tissue including an essential element for physiologically relevant tests for monitoring tissue viability.
Type:
Grant
Filed:
March 27, 2003
Date of Patent:
May 7, 2013
Assignees:
Hadasit Medical Research Services and Development Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem
Abstract: The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.
Type:
Grant
Filed:
March 18, 2010
Date of Patent:
April 16, 2013
Assignees:
Ben-Gurion University of the Negev Research and Development Authority, Hadasit Medical Research Services and Development Ltd.
Inventors:
Ofer Mandelboim, Angel Porgador, Yaakov Naparstek, Chamutal Gur
Abstract: An isolated polypeptide comprising an amino acid sequence at least 70% homologous to SEQ ID NO: 4 and an isolated polynucleotide encoding same are disclosed. A polynucleotide comprising a nucleic acid sequence capable of specifically hybridizing to the isolated polynucleotide and an isolated antibody comprising an antigen recognition domain which specifically binds the isolated polypeptide are also disclosed. Pharmaceutical compositions, methods of diagnosing and treating comprising same are also disclosed.
Type:
Application
Filed:
November 27, 2012
Publication date:
April 4, 2013
Applicants:
Hadasit Medical Research Services and Development Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
Inventors:
Yissum Research Development Company of the H, Hadasit Medical Research Services and Developm
Abstract: The present invention relates to genotypes associated with resistance to antipsychotic-induced parkinsonism and other extrapyramidal symptoms induced by antipsychotics, and use of said genotypes for assessment of patient populations. The methods and kits of the invention are based on identifying in a sample obtained from a subject, specific SNPs in the ZFPM2 and RGS2 genes.
Type:
Application
Filed:
May 26, 2011
Publication date:
March 28, 2013
Applicant:
HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
Inventors:
Bernard Lerer, Lior Greenbaum, Anna Alkelai